⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2600862 | 1.00 | — | — | |
| SCHEMBL516203 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL28657288 | 0.98 | TGFBR1 (0.39) | — | |
| Hydrochloric Acid SCHEMBL30478822 | 0.98 | TGFBR1 (0.39) | — | |
| SCHEMBL5195954 | 0.86 | MME (0.35) | — | |
| SCHEMBL19323313 | 0.84 | — | — | |
| SCHEMBL12155238 | 0.83 | SMN1; SMN2 (0.39) | — | |
| SCHEMBL11962066 | 0.83 | SMN1; SMN2 (0.39) | — | |
| SCHEMBL14224834 | 0.83 | SMN1; SMN2 (0.39) | — | |
| SCHEMBL8582497 | 0.82 | TGFBR1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724459-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Peptidream Inc (JP) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2024254339-A9 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-02 | — | — | US | disclosed |
| EP-4603105-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-20 | — | — | EP | disclosed |
| EP-4592308-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-30 | — | — | EP | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| CN-120202211-A | Cyclic compounds having selective KRAS inhibition over HRAS and NRAS | 中外制药株式会社 | 2025-06-24 | — | — | CN | disclosed |
| US-20250064968-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | GENENTECH, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| CN-114630835-B | Process for the preparation of peptide compounds comprising sterically bulky amino acids | 中外制药株式会社 | 2025-02-11 | — | — | CN | disclosed |
| US-9771378-B2 | Fused morpholinopyrimidines and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-8822474-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-20120302759-A1 | COMBRETASTATIN DERIVATIVE PREPARATION METHOD | C/O SANOFI (FR) | 2012-11-29 | — | — | US | disclosed |
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | POUZET PASCALE (US) | 2012-05-03 | — | — | US | disclosed |
| US-8114878-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-14 | — | — | US | disclosed |
| US-20120028905-A1 | Isolation, Purification, and Structure Elucidation of the Antiproliferative Compound Coibamide A | The State of Oregon, Acting by and through the State Board of Higher Education on behalf of | 2012-02-02 | — | — | US | disclosed |
| US-8034780-B2 | Isolation, purification, and structure elucidation of the antiproliferative compound coibamide A | SMITHSONIAN TROPICAL RESEARCH INSTITUTE | 2011-10-11 | — | — | US | disclosed |
| US-20090023642-A1 | Isolation, Purification, and Structure Elucidation of the Antiproliferative Compound Coibamide A | THE STATE OF OREGON, ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY | 2009-01-22 | — | — | US | disclosed |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-24 | — | — | US | disclosed |
| EP-0308983-A2 | NMR imaging with Mn(II) coordination compositions | SALUTAR, INC. (US) | 1989-03-29 | — | — | EP | disclosed |